Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REC-7735 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1A Dose Finding: REC-7735 | EXPERIMENTAL | Participants will receive REC-7735 twice daily (BID). |
| Phase 1B Dose Expansion/Optimization: REC-7735 | EXPERIMENTAL | Participants will receive REC-7735 BID. |
| Name | Type | Description |
|---|---|---|
| REC-7735 | DRUG | Oral |
Key Inclusion Criteria: * Participants have histologically-confirmed unresectable, locally advanced, or metastatic solid tumors which exhibit the PIK3CA H1047R mutation in tumor tissue and/or blood (circulating tumor deoxyribonucleic acid \[ctDNA\]). * For Phase 1A and planned monotherapy cohorts i...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
REC-7735 is an investigational small molecule drug being developed by Recursion Pharmaceuticals, Inc. for the treatment of solid tumors. It is currently in Phase 1 clinical development and is designed to target a specific mutation-driven form of cancer, with patient selection based on a biomarker.
REC-7735 is being studied for use in patients with solid tumors. It is an investigational therapy in Phase 1 testing, and its clinical program enrolls adults 18 years and older with solid tumor diagnoses. It has not been approved for any indication.
REC-7735 targets PI3K alpha, specifically the H1047R mutant form of the protein. PI3K alpha is a kinase involved in cell signaling, and the H1047R mutation is a known cancer-driving alteration. Targeting this mutant form is intended to focus activity on tumors carrying that mutation.
REC-7735 is being developed by Recursion Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker RXRX. Recursion is the sponsor of the drug's clinical program in solid tumors.
REC-7735 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 program is currently recruiting participants with solid tumors.
REC-7735 is being evaluated in one active clinical trial, NCT07819136, titled REC-7735 in Participants With Solid Tumors. The study is a Phase 1, controlled trial recruiting approximately 90 participants in the United States. It enrolls adults 18 years and older and is biomarker selected.